# Ranibizumab for Recalcitrant Wet Age-related Macular Degeneration in Eyes Previously Switched From Bevacizumab and/or Ranibizumab to Aflibercept.

> **NCT01972763** · PHASE1,PHASE2 · COMPLETED · sponsor: **Northern California Retina Vitreous Associates** · enrollment: 12 (actual)

## Conditions studied

- Recalcitrant Wet Age-related Macular Degeneration

## Interventions

- **DRUG:** Ranibizumab

## Key facts

- **NCT ID:** NCT01972763
- **Lead sponsor:** Northern California Retina Vitreous Associates
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10
- **Primary completion:** 2018-07
- **Final completion:** 2018-07
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2019-02-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01972763

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01972763, "Ranibizumab for Recalcitrant Wet Age-related Macular Degeneration in Eyes Previously Switched From Bevacizumab and/or Ranibizumab to Aflibercept.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01972763. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*